• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Accuray dives despite beating The Street as losses gape | Earnings Roundup

Accuray dives despite beating The Street as losses gape | Earnings Roundup

November 9, 2011 By MassDevice staff

Accuray

Accuray (NSDQ:ARAY) shares are down today after the radiosurgery company reported surging first-quarter sales and beat Wall Street’s earnings expectations, as investors reacted to net losses of nearly six times the Q1 2011 mark.

Accuray reported losses of $26.5 million, or 38 cents per share, on sales of $100.5 million for the three months ended Sept. 30. That’s top-line growth of 163.9 percent compared with the same period last year, largely due to the massive infusion that followed ARAY’s acquisition of rival TomoTherapy earlier this year.

But losses from the just-closed quarter dwarfed last year’s levels, rising more than 471 percent compared with $4.6 million, or 8 cents per share, in Q1 2011.

Sign up to get our free newsletters delivered straight to your inbox

Still, The Street was looking for adjusted losses of 40 cents per share, which Accuray handily beat – adjusted to exclude one-time items, losses were $11.0 million, or 16 cents per share.

That didn’t stop investors from driving ARAY shares down to $4.03 as of about 11 this morning, from their $4.24 close yesterday, a 5.0 percent drop.

“We are pleased with the steady progress being made with integrating the two companies, highlighted by improving service gross margins,” said president & CEO Euan Thomson said in prepared remarks. “The strong revenue generated in the first quarter is reflective of the growing interest in both CyberKnife and TomoTherapy technologies.”

Accuray said it expects to post fiscal 2012 revenues of between $409 million and $424 million.

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

CardioNet’s Q3 sales slip, losses narrow
CardioNet (NSDQ:BEAT) managed to pare its losses by nearly 5 percent during the third quarter, despite a 3.2 percent sales decline.

The remote cardiac monitoring firm reported losses of $7.1 million, or 29 cents per share, on sales of $26.6 million for the three months ended Sept. 30.

That compared with losses of $7.5 million, or 31 cents per share, on sales of $27.5 million during the same period last year. Read more

Electromed’s Q1 sales surge, profits soar
First-quarter profits for Electromed (NSDQ:ELMD) soared 119 percent on a 29.1 percent sales increase.

The airway clearance therapy maker reported profits of $246,000, or 3 cents per share, on sales of $5.4 million for the three months ended Sept. 30.

That compares with profits of $112,000, or 2 cents per share, on sales of $4.2 million during the same period last year. Read more

Kips Bay’s Q3 losses widen as sales fall to zero
Kips Bay Medical (NSDQ:KIPS) posted wider losses during the third quarter as its sales slid to zero.

The company reported losses of $1.2 million, or 8 cents per share, on no sales during the three months ended Oct. 1.

That compares with losses of $733,000, or 5 cents per share, on sales of $37,000 during the same period last year. Read more

Nobel Biocare slashes Q3 losses
Nobel Biocare (VTX:NOBN) slashed its third-quarter losses by more than 87 percent despite a slight sales decline.

The Swiss dental devices maker logged losses of $3.1 million (€2.2 million), or 3 cents (€0.02), on sales of $174.3 million (€128.2 million)during the quarter.

That compares with losses of $24.2 million (€2.2 million), or 19 cents (€0.14) per share, on sales of $179.1 million (€131.7 million) during the same period last year. Read more

Bioject swings to Q3 black
Bioject Medical Technologies (OTC:BJCT) posted third-quarter profits on 106.8 percent sales growth.

The drug delivery device maker reported profits of $372,000, or 1 cent per share, on sales of $3.1 million during the three months ended Sept. 30.

That compares with losses of $357,000, or 2 cents per share, on sales of $1.5 million during the same period last year. Read more

Q3 losses soar for Echo Therapeutics
Third-quarter losses soared for Echo Therapeutics (NSDQ:ECTE) on negative sales growth.

The transdermal drug delivery developer reported losses of $1.5 million, or 4 cents per share, on sales of -$44,000 for the three months ended Sept. 30.

That compares with losses of $620,000, or 2 cents per share, on sales of $47,000 during the same period last year. Read more

CasMed’s Q3 losses surge on flat sales
Third-quarter losses for CAS Medical Systems (NSDQ:CASM) surged on flat sales.

The patient monitoring firm posted losses of $2.1 million, or 16 cents per share, on sales of $5.8 million during the three months ended Sept. 30.

That compares with losses of $508,000, or 4 cents per share, on sales of $5.8 million during the same period last year. Read more

Cutera narrows losses, grows sales
Cutera (NSDQ:CUTR) pared its third-quarter losses on sales growth of 26 percent.

The cosmetic device maker reported losses of $2.9 million, or 21 cents per share, on sales of $15.2 million during the three months ended Sept. 30.

That compares with losses of $3.5 million, or 18 cents per share, on sales of $12.1 million during the same period last year. Read more

IntriCon swings to Q3 red
IntriCon (NSDQ:IIN) logged third-quarter losses on a 5.8 percent sales slide.

The miniature medical device maker reported losses of $489,000, or 9 cents per share, on sales of $13.9 million.

That compares with profits of $243,000, or 4 cents per share, on sales of $14.7 million during the same period last year. Read more

Tornier’s Q3 sales jump as it slashes losses
Tornier (NSDQ:TRNX) slashed its third-quarter losses via a 15.8 percent sales boost.

The extremity joint replacement company posted losses of $1.6 million, or 4 cents per share, on sales of $57.6 million for the three months ended Oct. 2.

That compares with losses of $12.8 million, or 43 cents per share, on sales of $49.7 million during the same period last year. Read more

BioMimetic Therapeutics shaves losses on sales growth
BioMimetic Therapeutics (NSDQ:BMTI) shaved 8.1 percent off its third-quarter losses with 21.4 percent sales growth.

The biotech firm reported losses of $7.1 million, or 25 cents per share, on sales of $429,000 for the three months ended Sept. 30.

That compares with losses of $7.8 million, or 29 cents per share, on sales of $353,000 during the same period last year. Read more

Pro-Dex
Pro-Dex posts Q1 sales, earnings growth
Pro-Dex (NSDQ:PDEX) logged first-quarter growth for both its top and bottom lines.

The surgical device drive maker reported profits of $446,000, or 14 cents per share, on sales of $6.0 million during the three months ended Sept. 30.

That compares with profits of $342,000, or one thin dime per share, on sales of $5.8 million during the same period last year. Read more

Misonix logs Q1 sales growth, narrows losses Misonix (NSDQ:MSON) narrowed its first-quarter losses on 14.8 percent sales growth.

The ultrasound device maker reported losses of $884,000, or 13 ce3nts per share, on sales of $3.7 million during the three months ended Sept. 30.

That compares with losses of $1.0 million, or 15 cents per share, on sales of $3.3 million during the same period last year. Read more

Filed Under: MassDevice Earnings Roundup, News Well, Radiosurgery/Radiation therapy Tagged With: Accuray Inc., Bioject Medical Technologies Inc., BioMimetic Therapeutics Inc., CardioNet Inc., CAS Medical Systems Inc., Cutera Inc., Echo Therapeutics Inc., Electromed, IntriCon Corp., Kips Bay Medical Inc., Misonix, Nobel Biocare Holdings AG, Pro-Dex Inc., Q3, Tornier Inc.

In case you missed it

  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

RSS From Medical Design & Outsourcing

  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS